검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… ORR 6.35% | ||
|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | TNFi (Tumor Necrosis Factor inhibitor) medication |
Overview Company | AbbVie | Amgen / Pfizer | Bristol-Myers Squibb |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF | Polyarticular Course Juvenile Idiopathic |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, psoriasis, psoriatic arthritis, ankylosing spondylitis | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING |
MoA Mechanism | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | Decoy receptor for TNF-α and lymphotoxin | — |
MoA Biomarker | biomarkers to support personalized treatment strategies | ACR20, PASI75 | — |
PK/PD Half-life | — | 30 h | — |
PK/PD Species | Rat, xenografts, which corroborat | Rat | — |
PK/PD Animal (cat.) | Rat | Rat, In vitro | — |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | — |
Toxicology Species | Rat, xenografts, which corroborat | Rat | — |
Toxicology Animal (cat.) | Unknown | Unknown | — |
Toxicology Major finding | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | interstitial lung disease Skin and subcutaneous tissue disorders: cutaneous lupus erythematosus, | Possible Association Between Etanercept Use During Breastfeeding and Infant Somnolence, Hypotonia, and Feeding Difficulties: A Case Report and Literature Review.. Etanercept is a tumor necrosis factor inhibitor frequently used to control ankylosing spondylitis (AS) in women of reproductive age, yet data on its safety during breastfeeding are limited. We report a case of an infant who developed som… |
Clinical Primary efficacy | ORR 98.85% | ORR 73.4% | ORR 6.35% |
Clinical PASI75 | — | PASI 75 response rate at Week 12. | — |
Clinical ORR | 98.85% | 73.4% | 6.35% |
Clinical Result source | ClinicalTrials.gov NCT00427921 | ClinicalTrials.gov NCT01891864 | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | S · 92 | B · 91 | C · 43 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 7월 18일 (3일 전) | 2026년 7월 6일 (16일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… ORR 6.35% | ||
|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | TNFi (Tumor Necrosis Factor inhibitor) medication |
Overview Company | AbbVie | Amgen / Pfizer | Bristol-Myers Squibb |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF | Polyarticular Course Juvenile Idiopathic |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, psoriasis, psoriatic arthritis, ankylosing spondylitis | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING |
MoA Mechanism | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors | Decoy receptor for TNF-α and lymphotoxin | — |
MoA Biomarker | biomarkers to support personalized treatment strategies | ACR20, PASI75 | — |
PK/PD Half-life | — | 30 h | — |
PK/PD Species | Rat, xenografts, which corroborat | Rat | — |
PK/PD Animal (cat.) | Rat | Rat, In vitro | — |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | — |
Toxicology Species | Rat, xenografts, which corroborat | Rat | — |
Toxicology Animal (cat.) | Unknown | Unknown | — |
Toxicology Major finding | Interstitial lung disease, including pulmonary fibrosis, pulmonary embolism Skin reactions: Steve | interstitial lung disease Skin and subcutaneous tissue disorders: cutaneous lupus erythematosus, | Possible Association Between Etanercept Use During Breastfeeding and Infant Somnolence, Hypotonia, and Feeding Difficulties: A Case Report and Literature Review.. Etanercept is a tumor necrosis factor inhibitor frequently used to control ankylosing spondylitis (AS) in women of reproductive age, yet data on its safety during breastfeeding are limited. We report a case of an infant who developed som… |
Clinical Primary efficacy | ORR 98.85% | ORR 73.4% | ORR 6.35% |
Clinical PASI75 | — | PASI 75 response rate at Week 12. | — |
Clinical ORR | 98.85% | 73.4% | 6.35% |
Clinical Result source | ClinicalTrials.gov NCT00427921 | ClinicalTrials.gov NCT01891864 | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | S · 92 | B · 91 | C · 43 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 7월 18일 (3일 전) | 2026년 7월 6일 (16일 전 · 갱신 권장) |
추천 비교
추천 비교